Pharm for Viral Hepatitis Flashcards

1
Q

What kind of genome does HCV have?

A

ssRNA

corrected (said ssDNA before. This was a typo. HBV is the only DNA hepatitis virus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are HCV gene products translated?

A

As a polyprotein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What accounts for the high mutation rate in HCV?

A

viral RNA-dependent RNA polymerase lacks proofreading (like in HIV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Does HCV genotype affect severity of liver injury?

A

No, but it does affect response to therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Once a patient has cirrhosis, what’s the risk of progressing to HCC or decompensated cirrhosis?

A

5% / year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Factors that increase rate of progression to HCC / decompensated cirrhosis in HCV?

A
Age > 40
Male 
Caucasian/Hispanic
Smoking
Other liver injury (EtOH, HBV, etc)
Immunocompromise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What does “on treatment viral kinetics” mean? Significance?

A

The rate at which viral load drops with therapy.

Faster drop predicts higher chance of sustained viral response (SVR).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What’s the definition of sustained viral response (SVR)? Significance?

A

Absence of detectable HCV 6mo after cessation of therapy.
SVR is in most cases a cure - chance of relapse after SVR is < 1%.
Additionally, risk of HCC is greatly reduced and risk of decompensation is almost eliminated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment for HCV prior to 2011?

A

PEGylated interferon-alpha (IFN) + ribavirin (RBV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Potential MoAs of IFN?

Take-home points about it?

A

Immune activation - more MHC-I, more CTLs and NKs, more macrophage activity.
Direct antiviral activity - inhibits HCV attachment/uncoating, activation of RNAses.

Take-home points: Because IFN activates immune system it… 1. Makes you feel like crap. 2. Is less prone having HCV become resistant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What affect does PEGylation of IFN have?

A

Increases half life - more sustained levels throughout therapy, and only needs to be given 1x/week.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Major adverse effects of IFN?

A

Flu-like symptoms
Depression, suicidial ideation
Pancytopenia
Activates autoimmune disease (eg. thyroiditis)
Cachexia
Increased bacterial infection risk (esp. cirrhosis)
Worsening of liver function (esp. in cirrhosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What’s the structure of ribavirin (RBV)?

What’s its MoA?

A

It’s a guanosine analogue that inhibits HCV’s RNA polymerase.
(also it induces mutations, depletes GTP, and makes T cell response favor Th1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What’s the utility of RBV for HCV?

A

Useless on it own, but increases rate of SVR when given with IFN. (decreases rate of relapse)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adverse effects of RBV?

A
Non-immune hemolytic anemia
Rash
Dyspnea
Teratogenic
-Also excreted renally and not dialyzable, so must be used with caution in pts with renal failure.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do SVR rates compare in HCV Genotype 1 vs. Genotypes 2,3 with IFN + RBV?

A

40% SVR rate for Genotype 1

80% for Genotypes 2,3

17
Q

2 currently approved HCV protease inhibitors?

A

Telaprevir (TPV) and Boceprevir (BOC)

18
Q

2 anti-HCV drugs soon to be approved?

A

Sofobuvir (polymerase inhibitor)

Simeprevir (protease inhibtor)

19
Q

What happens if you give a directly-acting antiviral as monotherapy?

A

Resistance. (just like HIV)

20
Q

For what genotype(s) of HCV do TPV and BOC work?

A

Only for genotype 1.

21
Q

As of 2011, what’s the current treatment for HCV Genotype 1?

A

IFN + RBV + TPV or BOC

- Raised SVR rate to 70%. Should be even higher with new drugs coming out…

22
Q

Does HBV replication directly damage hepatocytes?

A

Not really. It’s mostly due to the immune response.

But… a robust immune makes it more likely that an acute infection will be cleared.

23
Q

What does “eAg seroconversion” refer to?

A

Immune system catches up and mounts response to replicating virus. It starts making Abs to eAg, and the eAg disappears.
(this is a good thing for the patient)

24
Q

How does HBV often avoid antibodies to eAg?

A

It mutates eAg. This is how you can have eAg-negative chronic Hep B.

25
Q

Should you treat inactive carriers of HBV?

A

No. but they should be monitored for switching back to active disease.

26
Q

2 realistic endpoints of HBV therapy?

A

eAg seroconversion.
Reduction in HBV DNA levels.
(loss of HBsAg is very rare)

27
Q

Can IFN be used for HBV? Does it work better or worse for particular types?

A

Yes. It works better for eAg-positive HepB than for eAg-negative (but doesn’t work very well for either).

28
Q

Adverse effects of oral antivirals for HBV?

A

They’re actually very well tolerated.

29
Q

Can you use HBV direct antivirals long term?

A

Yep. Not so for IFN.